Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of July, 2023

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended July 31, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:




Ordinary Shares


Volume Weighted

Average Price Paid

per Ordinary Share


Highest Price Paid


Lowest Price Paid

July 3, 2023

   52,542    221.63p    223.50p    219.50p

July 4, 2023

   50,808    224.50p    226.00p    218.00p

July 5, 2023

   50,935    224.80p    228.00p    220.50p

July 6, 2023

   48,119    222.82p    224.50p    221.50p

July 7, 2023

   45,925    218.46p    220.50p    216.00p

July 10, 2023

   49,838    220.49p    221.50p    218.00p

July 11, 2023

   49,568    220.08p    222.00p    218.50p

July 12, 2023

   49,535    222.03p    225.50p    219.00p

July 13, 2023

   47,674    219.71p    220.00p    217.00p

July 14, 2023

   49,341    215.62p    218.50p    214.50p

July 17, 2023

   42,082    214.16p    218.00p    211.50p

July 18, 2023

   42,100    212.97p    218.00p    210.50p

July 19, 2023

   41,397    225.33p    227.50p    221.00p

July 20, 2023

   20,040    227.11p    227.50p    224.50p

July 21, 2023

   43,256    229.62p    230.00p    227.00p

July 24, 2023

   42,666    227.86p    232.00p    224.50p

July 25, 2023

   35,701    225.57p    227.50p    219.50p

July 26, 2023

   37,881    228.14p    231.00p    226.00p

July 27, 2023

   34,923    227.91p    230.50p    226.00p

July 28, 2023

   37,075    228.79p    230.00p    226.00p

July 31, 2023

   34,963    226.31p    229.50p    222.50p

During the month ended July 31, 2023, the Company repurchased an aggregate of 906,369 Ordinary Shares. As of July 31, 2023, the Company’s issued share capital was 289,468,159 shares, 13,409,665 of which were held in treasury, resulting in total voting rights in the Company of 276,058,494 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

July 3, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4823588.html

July 4, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4825010.html

July 5, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4826362.html

July 6, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4827960.html

July 7, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4829449.html

July 10, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4830934.html

July 11, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4832444.html

July 12, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4833862.html

July 13, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4835234.html

July 14, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4836731.html

July 18, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4839640.html

July 19, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4841104.html

July 20, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4842539.html

July 21, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4843990.html

July 24, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4845558.html

July 25, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4847060.html

July 26, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4848529.html

July 27, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4850197.html

July 28, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4851670.html

July 31, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4853443.html


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: August 2, 2023   By:   /s/ Daphne Zohar
    Name:   Daphne Zohar
    Title:   Chief Executive Officer